Saturday, February 14, 2026 2/14/2026

Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials

Award Number: R01AI157208
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/23/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials - The rapid emergence of antimicrobial resistance presents a significant challenge for treatment of bacterial infections. Carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii, and Pseudomonas aeruginosa are of particular concern. We are clearly in need of several new Gram-negative agents that are unique in terms of liabilities and antimicrobial class and which can diversify our antimicrobial development portfolio. This multi-PI proposal investigates natural products called streptothricins, which contain three moieties: streptolidine, a gulosamine sugar, and a single β-lysine or poly-β-lysine chain of varying length. Streptothricins were identified over 70 years ago and inhibit protein translation with extensive protein miscoding. In preliminary experiments, we determined that streptothricins (the natural product mixture is also called nourseothricin) are broadly active against multidrug-resistant Gram-negative pathogens. In particular, for streptothricin-F, which has a single β-lysine moiety, we identified compelling activity in vitro and in vivo. However, several streptothricin acetyl transferases, found in low frequency in Gram-negative pathogens, confer streptothricin resistance by acetylation of the β-amine of the β-lysine residue. These observations led to our hypothesis that antibacterial activity can be separated from toxicities and at the same time these antibiotic resistance elements blocked through derivatization/replacement of the β-lysine moiety and other constituents. Therefore, the goals of this proposal are to use an efficient, diversity- oriented, medicinal chemistry synthesis of streptothricin analogues to perform hypothesis-driven structure- activity relationship studies to optimize therapeutic properties of this scaffold. In particular, we propose to functionally profile each streptothricin analogue to determine potency against problematic Gram-negative pathogens, selectivity for prokaryotic ribosomes, toxicity, and metabolic stability. Prioritized analogues will be tested in a mouse model for toxicity, drug clearance, and therapeutic efficacy. Furthermore, prioritized analogues will be investigated in cryo-EM based-structural and auto-docking studies to understand how these molecular variants differentially bind to the A. baumannii 70S ribosome. Structural insights from these studies will be used to provide iterative feedback to optimize design of analogues during the course of the proposed work. Taken together, the experiments in the aims of the proposal will address the lack of systematic exploration in the streptothricin literature and identify molecular constituents that are amenable to productive modification to enhance properties of this scaffold as a future therapeutic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	5	8/11/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $761,258 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	5	7/25/2024	NON-COMPETING CONTINUATION	$761,258
														Subtotal = $761,258

Issue Date FY: 2023 ( Subtotal = $766,825 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	4	8/15/2023	NON-COMPETING CONTINUATION	$766,825
														Subtotal = $766,825

Issue Date FY: 2022 ( Subtotal = $772,231 )
2022	2022	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	3	8/18/2022	NON-COMPETING CONTINUATION	$772,231
														Subtotal = $772,231

Issue Date FY: 2021 ( Subtotal = $777,478 )
2021	2021	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	2	8/12/2021	NON-COMPETING CONTINUATION	$777,478
														Subtotal = $777,478

Issue Date FY: 2020 ( Subtotal = $818,324 )
2020	2020	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	9/23/2020	NEW	$818,324
														Subtotal = $818,324

Grand Total All Awards = $3,896,116

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials

Award Number: R01AI157208

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/23/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer